Researchers validate preclinical effectiveness of TB drug target

( SRI International ) In research at SRI International, scientists evaluating new drug targets against tuberculosis recently validated the preclinical effectiveness of a target that could rapidly eliminate infections and potentially shorten treatment time. The new drug target is a protein called DNA gyrase B, found in bacteria that cause TB infections.

Leave a Reply

Your email address will not be published.

*